Diakonos Oncology Corp., a Houston, TX-based clinical-stage biotechnology firm growing a brand new technology of immunotherapies to deal with difficult and aggressive cancers, closed a $20m personal placement of Easy Agreements for Future Fairness (SAFE).
The financing included backing by new traders Baylor School of Medication (BCM), the Mind Tumor Funding Fund (BTIF), and the Buttonwood Titan QC Fund, with extra participation from present shareholders together with CEO Mike Wicks, MS. BCM can also be contributing in-kind companies towards the corporate’s pre-clinical and medical growth packages.
The corporate intends to make use of the funds to speed up its Section 2 glioblastoma trial for dubodencel, also referred to as DOC1021, and develop its medical portfolio to different indications, together with refractory melanoma. This $20m financing follows an $11.4m seed financing that closed final 12 months and serves as a bridge to a Sequence A financing that the corporate plans to launch within the second half of this 12 months.
Led by Mike Wicks, CEO, and Jay Hartenbach, President and Chief Working Officer, Diakonos Oncology is a clinical-stage biotechnology firm devoted to advancing most cancers immunotherapy with its proprietary double-loaded, patient-derived dendritic cell therapeutic platform targeted on addressing the important, unmet medical want for therapy of late-state and aggressive cancers.
Dubodencel, also referred to as DOC1021, is a first-in-class, double-loaded autologous dendritic cell remedy that mixes tumor lysate and amplified tumor-derived mRNA. The immunotherapy is made with a affected person’s dendritic cells mixed with mRNA and proteins ready from freshly obtained affected person tumor specimens.
FinSMEs
01/06/2025
